Released Mar 10, 2022, before the open
10-K filed Mar 10, 2022, 69 days after period end · 0001628280-22-005753
Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$713.00K$713.00K derived+184.1% vs Q4 2020+1,639.0% vs Q3 2021
Net Income-$29.14M-$29.14M derivedN/M vs Q4 2020N/M vs Q3 2021
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$28,082,000N/M
Operating Cash Flowderived$11,882,000N/M
Free Cash Flowderived$11,802,000N/M
Margins · derived
Operating margin-3938.6%+4339.9 pt vs Q4 2020
Net margin-4087.4%+4182.7 pt vs Q4 2020
What the release said
The release
Same quarter
| Metric | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures |
|---|---|---|---|
| Revenue | $713.00K | $251.00K | — |
| Net Income | -$29.14M | -$20.76M | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR